Published in J Immunol on October 01, 1985
Role of tryptophan degradation in respiratory burst-independent antimicrobial activity of gamma interferon-stimulated human macrophages. Infect Immun (1989) 2.25
Regulation of human immunodeficiency virus type 1 and cytokine gene expression in myeloid cells by NF-kappa B/Rel transcription factors. Microbiol Rev (1995) 1.63
Pathogenicity of Mycobacterium avium for human monocytes: absence of macrophage-activating factor activity of gamma interferon. Infect Immun (1989) 1.52
Hydrogen peroxide release by alveolar macrophages from sarcoid patients and by alveolar macrophages from normals after exposure to recombinant interferons alpha A, beta, and gamma and 1,25-dihydroxyvitamin D3. J Clin Invest (1987) 1.28
Reduction in intensity of Pneumocystis carinii pneumonia in mice by aerosol administration of gamma interferon. Infect Immun (1991) 1.25
Treatment of toxoplasmic encephalitis in mice with recombinant gamma interferon. Infect Immun (1990) 1.24
Alveolar macrophages in AIDS patients: increased spontaneous tumour necrosis factor-alpha production in Pneumocystis carinii pneumonia. Clin Exp Immunol (1990) 1.23
Microbicidal activity of monocyte derived macrophages in AIDS and related disorders. Clin Exp Immunol (1987) 1.23
Oxygen-independent killing by alveolar macrophages. J Exp Med (1986) 1.11
Prevention of infection due to Pneumocystis carinii. Antimicrob Agents Chemother (1998) 1.11
Organ specific cytokine therapy. Local activation of mononuclear phagocytes by delivery of an aerosol of recombinant interferon-gamma to the human lung. J Clin Invest (1991) 1.06
Nonoxidative microbicidal activity in normal human alveolar and peritoneal macrophages. Infect Immun (1987) 1.01
Activation of pulmonary macrophages for fungicidal activity by gamma-interferon or lymphokines. Clin Exp Immunol (1987) 1.00
Preservation of monocyte effector functions against Mycobacterium avium-M. intracellulare in patients with AIDS. Infect Immun (1991) 0.96
Gamma interferon stimulates rat alveolar macrophages to kill Pneumocystis carinii by L-arginine- and tumor necrosis factor-dependent mechanisms. Infect Immun (1999) 0.93
Differences in microbicidal activities of human macrophages against Toxoplasma gondii and Trypanosoma cruzi. Infect Immun (1990) 0.92
Cross-protective immunity of mice induced by oral immunization with pneumococcal surface adhesin a encapsulated in microspheres. Infect Immun (2002) 0.89
Effect of IFN-gamma on the proliferation of Toxoplasma gondii in monocytes and monocyte-derived macrophages from AIDS patients. Immunology (1994) 0.85
AIDS and the lung: update 1995. 4. Role of the human immunodeficiency virus within the lung. Thorax (1995) 0.85
Reduced oxidative burst responses in monocytes and monocyte-derived macrophages from HIV-infected subjects. Clin Exp Immunol (1990) 0.85
The immunocompromised host: HIV infection. Proc Am Thorac Soc (2005) 0.84
Cellular immunology of HIV-infection. Clin Exp Immunol (1988) 0.83
Generation of superoxide anion by alveolar macrophages in sarcoidosis: evidence for the activation of the oxygen metabolism in patients with high-intensity alveolitis. Immunology (1989) 0.83
Abnormalities in host defense associated with HIV infection. Clin Chest Med (2013) 0.81
Protective immunity of microsphere-based mucosal vaccines against lethal intranasal challenge with Streptococcus pneumoniae. Infect Immun (1999) 0.80
Granulocyte-macrophage colony-stimulating factor (GM-CSF) reduces toxoplasmastatic activity of human monocytes via induction of prostaglandin E2 (PGE2). Clin Exp Immunol (1995) 0.77
Ultraviolet-irradiated monocytes efficiently inhibit the intracellular replication of Mycobacterium avium intracellulare. J Clin Invest (1992) 0.76
Immunology of HIV infection and AIDS: memorandum from a WHO/IUIS meeting. Bull World Health Organ (1987) 0.75
Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J Exp Med (1983) 14.08
Early Lung Cancer Action Project: overall design and findings from baseline screening. Lancet (1999) 13.67
An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med (1981) 7.35
Killing of intracellular Leishmania donovani by lymphokine-stimulated human mononuclear phagocytes. Evidence that interferon-gamma is the activating lymphokine. J Clin Invest (1983) 5.88
Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med (1984) 4.73
The macrophage as an effector cell. N Engl J Med (1980) 4.30
Activation of mouse peritoneal macrophages in vitro and in vivo by interferon-gamma. J Immunol (1985) 3.85
Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon. Proc Natl Acad Sci U S A (1983) 3.83
Impaired production of lymphokines and immune (gamma) interferon in the acquired immunodeficiency syndrome. N Engl J Med (1984) 3.73
Macrophage oxygen-dependent antimicrobial activity. II. The role of oxygen intermediates. J Exp Med (1979) 3.72
Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis (2000) 3.72
Interaction between the legionnaires' disease bacterium (Legionella pneumophila) and human alveolar macrophages. Influence of antibody, lymphokines, and hydrocortisone. J Clin Invest (1984) 3.59
Rapid accurate field diagnosis of Indian visceral leishmaniasis. Lancet (1998) 3.55
Gamma-interferon is the factor in lymphokine that activates human macrophages to inhibit intracellular Chlamydia psittaci replication. J Immunol (1983) 3.49
Macrophage oxygen-dependent antimicrobial activity. III. Enhanced oxidative metabolism as an expression of macrophage activation. J Exp Med (1980) 3.43
Killing of intracellular Leishmania donovani by human mononuclear phagocytes. Evidence for oxygen-dependent and -independent leishmanicidal activity. J Clin Invest (1983) 3.06
The protean manifestations of Mycoplasma pneumoniae infection in adults. Am J Med (1975) 3.06
Activation of human macrophages. Comparison of other cytokines with interferon-gamma. J Exp Med (1984) 3.02
Macrophage oxygen-dependent antimicrobial activity. I. Susceptibility of Toxoplasma gondii to oxygen intermediates. J Exp Med (1979) 2.93
A cluster of Pneumocystis carinii pneumonia in adults without predisposing illnesses. N Engl J Med (1991) 2.80
Familial dysautonomia is caused by mutations of the IKAP gene. Am J Hum Genet (2001) 2.67
Serious infections from Bacillus sp. JAMA (1979) 2.67
Streptococcus bovis bacteremia and underlying gastrointestinal disease. Arch Intern Med (1978) 2.54
Serious infections caused by Streptococcus milleri. Am J Med (1978) 2.47
Experimental visceral leishmaniasis: production of interleukin 2 and interferon-gamma, tissue immune reaction, and response to treatment with interleukin 2 and interferon-gamma. J Immunol (1987) 2.45
Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol (2003) 2.43
Cell-mediated immune response in experimental visceral leishmaniasis. I. Correlation between resistance to Leishmania donovani and lymphokine-generating capacity. J Immunol (1982) 2.42
Liver macrophages in murine listeriosis. Cell-mediated immunity is correlated with an influx of macrophages capable of generating reactive oxygen intermediates. J Exp Med (1985) 2.37
Interrelationships of human interferon-gamma with lymphotoxin and monocyte cytotoxin. J Exp Med (1984) 2.33
Interleukin 2 regulates the expression of Tac antigen on peripheral blood T lymphocytes. J Exp Med (1984) 2.26
Role of tryptophan degradation in respiratory burst-independent antimicrobial activity of gamma interferon-stimulated human macrophages. Infect Immun (1989) 2.25
Differential efficacies of human type I and type II interferons as antiviral and antiproliferative agents. Proc Natl Acad Sci U S A (1980) 2.24
Susceptibility of Leishmania to oxygen intermediates and killing by normal macrophages. J Exp Med (1981) 2.22
Effect of interferon on the growth of Chlamydia trachomatis in mouse fibroblasts (L cells). Infect Immun (1983) 2.17
The anticellular and protein-inducing activities of human gamma interferon preparations are mediated by the interferon. J Immunol (1983) 2.13
Cell-mediated immune response in experimental visceral leishmaniasis. II. Oxygen-dependent killing of intracellular Leishmania donovani amastigotes. J Immunol (1982) 2.09
Murine Kupffer cells. Mononuclear phagocytes deficient in the generation of reactive oxygen intermediates. J Exp Med (1985) 2.03
Interferon-induced guanylate binding protein-1 (GBP-1) mediates an antiviral effect against vesicular stomatitis virus and encephalomyocarditis virus. Virology (1999) 2.02
High affinity binding of 125I-labeled human tumor necrosis factor (LuKII) to specific cell surface receptors. J Exp Med (1985) 2.00
Human mononuclear phagocyte antiprotozoal mechanisms: oxygen-dependent vs oxygen-independent activity against intracellular Toxoplasma gondii. J Immunol (1985) 2.00
Lymphokine enhances oxygen-independent activity against intracellular pathogens. J Exp Med (1983) 1.93
Comparative analysis of the influences of human gamma, alpha and beta interferons on human multipotential (CFU-GEMM), erythroid (BFU-E) and granulocyte-macrophage (CFU-GM) progenitor cells. J Immunol (1983) 1.88
Circulating Borrelia burgdorferi in patients with acute Lyme disease: results of blood cultures and serum DNA analysis. J Infect Dis (1993) 1.88
Spectrum of pulmonary diseases associated with the acquired immune deficiency syndrome. Am J Med (1985) 1.88
Atypical pneumonias. Med Clin North Am (1980) 1.88
Oxygen-independent inhibition of intracellular Chlamydia psittaci growth by human monocytes and interferon-gamma-activated macrophages. J Immunol (1986) 1.87
IFN-gamma-activated human alveolar macrophages inhibit the intracellular multiplication of Legionella pneumophila. J Immunol (1988) 1.87
Role of L3T4+ and LyT-2+ cells in experimental visceral leishmaniasis. J Immunol (1988) 1.87
Patients at risk for AIDS-related opportunistic infections. Clinical manifestations and impaired gamma interferon production. N Engl J Med (1985) 1.87
Short-course, low-dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony. Ann Intern Med (1997) 1.80
Malaria--the mime revisited: fifteen more years of experience at a New York City teaching hospital. Am J Med (1992) 1.77
Nonhematopoietic cells selected for resistance to tumor necrosis factor produce tumor necrosis factor. J Exp Med (1986) 1.77
Interferon action: induction of specific proteins in mouse and human cells by homologous interferons. Proc Natl Acad Sci U S A (1979) 1.76
Prophylaxis against ampicillin-associated diarrhea with a lactobacillus preparation. Am J Hosp Pharm (1979) 1.72
Tumor cell anti-oxidant defenses. Inhibition of the glutathione redox cycle enhances macrophage-mediated cytolysis. J Exp Med (1981) 1.71
Experimental visceral leishmaniasis: role of endogenous IFN-gamma in host defense and tissue granulomatous response. J Immunol (1989) 1.70
Salmonella infections in patients with the acquired immunodeficiency syndrome. Ann Intern Med (1985) 1.69
Regulation of arachidonic acid metabolism by macrophage activation. J Exp Med (1982) 1.69
Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis. Infect Immun (1994) 1.67
Patients treated for amebic liver abscess develop cell-mediated immune responses effective in vitro against Entamoeba histolytica. J Immunol (1986) 1.65
Diagnosis of pulmonary disease in acquired immune deficiency syndrome (AIDS). Role of bronchoscopy and bronchoalveolar lavage. Am Rev Respir Dis (1984) 1.60
Intracellular antimicrobial activity in the absence of interferon-gamma: effect of interleukin-12 in experimental visceral leishmaniasis in interferon-gamma gene-disrupted mice. J Exp Med (1997) 1.59
Trial of oral miltefosine for visceral leishmaniasis. Lancet (1998) 1.58
Immunochromatographic strip-test detection of anti-K39 antibody in Indian visceral leishmaniasis. Ann Trop Med Parasitol (2002) 1.54
T4+ cell production of interferon gamma and the clinical spectrum of patients at risk for and with acquired immunodeficiency syndrome. Arch Intern Med (1988) 1.53
The dynamics of granuloma formation in experimental visceral leishmaniasis. J Exp Med (1988) 1.51
In vitro and in vivo activation of human mononuclear phagocytes by interferon-gamma. Studies with normal and AIDS monocytes. J Immunol (1987) 1.51
Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ (2001) 1.50
Antistreptolysin O and anti-deoxyribonuclease B titers: normal values for children ages 2 to 12 in the United States. Pediatrics (1998) 1.50
Splenic cytokine responses in Indian kala-azar before and after treatment. J Infect Dis (1998) 1.49
Septic pulmonary embolism complicating a central venous catheter. Chest (1990) 1.47
Oral fluconazole therapy for patients with acquired immunodeficiency syndrome and cryptococcosis: experience with 22 patients. Am J Med (1988) 1.45
Macrophage oxygen-dependent antimicrobial activity. IV. Role of endogenous scavengers of oxygen intermediates. J Exp Med (1980) 1.44
Role and effect of TNF-alpha in experimental visceral leishmaniasis. J Immunol (1994) 1.43
Circulating T helper 1 (Th1) cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis. Am J Trop Med Hyg (1997) 1.43
Interaction of Leishmania with a macrophage cell line. Correlation between intracellular killing and the generation of oxygen intermediates. J Exp Med (1981) 1.34
Noninvasive management of Indian visceral leishmaniasis: clinical application of diagnosis by K39 antigen strip testing at a kala-azar referral unit. Clin Infect Dis (2002) 1.33
Pretreatment with phorbol myristate acetate inhibits macrophage activity against intracellular protozoa. J Reticuloendothel Soc (1982) 1.32
Coping with AIDS. The special problems of New York City. N Engl J Med (1987) 1.31
Antimicrobial therapy in pulmonary aspiration. Am J Med (1979) 1.31
Purification and characterization of a human tumor necrosis factor from the LuKII cell line. Proc Natl Acad Sci U S A (1985) 1.29